Abstract: This invention involves the establishment of manufacture of clinically useful controlled release parenteral formulation of buprenorphine hydrochloride/buprenorphine base microparticle delivery system. Buprenorphine and buprenorphine hydrochloride has been used for the treatment of pain and drug addiction. In view of minimizing the frequency of dosing and avoiding surgical procedures, controlled release parenteral dosage forms are developed using biocompatible and biodegradable polymers. These parenteral formulations also avoid oral absorption problems and potential abuse associated with other possible forms of administration such as sublingual, nasal and transdermal dosage forms. Poly-(lactic acid), poly-(glycolic acid) and their copolymers and mixture of these polymers are used for the development of microencapsulation of a buprenorphine and buprenorphine hydrochloride by solvent evaporation from oil/water emulsion.

Abstract: Taught is a process for purifying a benzoquinoid ansamycin antibiotic such as geldanamycin through the use of a fluid comprising supercritical carbon dioxide. In certain embodiments the fluid also includes an aliphatic alcohol such as methanol or ethanol.

Abstract: A process for supercritical fluid extraction of delta-9-tetrahydrocannabinol (delta-9-THC), delta-8-THC, cannabinoids or other medicinal value compounds from marijuana and other plants. Preferably, the extraction is carried out with a solvent of liquid carbon dioxide alone, or in combination with a solvent of ethanol, methanol, isopropanol, and other nonpolar/semipolar solvents at a temperature and pressure to maintain the solvents in a supercritical state. The extraction process is preferably carried out for a period of from 0 to 9 hours. The extraction process conditions result in different strengths of extracted marijuana and selective isolation of extracted compounds or mixtures of compounds.

Abstract: A transdermal/transcutaneous delivery system to deliver Tetrahydrocannabinol (THC) and related compounds, comprising of gel, film and reconstituted liquid for topical application. The delivery system may contain polymethacrylic acid (PMA), carbopol, polyethylene glycol 8000 (PEG), propylene glycol (PG), water, alcohol, acetone, caprylic acid, caproic acid, oleic acid, lauric acid, isopropyl myristate, triethanolamine, and mixtures thereof. This formulation can be used as an analgesic, antiemetic, antiglaucoma medication, arthritis treatment and prevention of weight loss treatment associated with AIDS. It can also be used for treating dementia and multiple sclerosis. The present formulation avoids the problems associated with oral administration, patient compliance and potential abuse associated with other routes of administration of THC.